Biogen Inc. (NASDAQ:BIIB) is one in all one of the best performing pharma shares in 2025. Biogen Inc. (NASDAQ:BIIB) obtained a number of score updates on January 8. Truist lifted the worth goal on the inventory to $190 from $142 however maintained a Maintain score, telling buyers in a analysis word that whereas it up to date its mannequin, the basic views stay the identical as 2025.
The identical day, Biogen Inc. (NASDAQ:BIIB) additionally obtained score updates from Goldman Sachs and Mizuho. Goldman Sachs raised the worth goal on the inventory to $225 from $197 whereas protecting a Purchase score on the shares. It expects momentum to proceed in 2026 after sturdy sector efficiency in 2025, supported by enhancing fundamentals, market dynamics, and easing coverage dangers. These components, together with their secondary results comparable to M&A, persist, in keeping with the agency.
Mizuho, then again, lifted the worth goal on Biogen Inc. (NASDAQ:BIIB) to $207 from $177 and maintained an Outperformed score, stating that it up to date the corporate’s mannequin since 2026 is “trying a bit higher” for Biogen Inc. (NASDAQ:BIIB).
Biogen Inc. (NASDAQ:BIIB) is a worldwide biopharmaceutical firm that discovers, develops, and delivers superior therapies for critical illnesses throughout the globe. Its medication portfolio treats a number of sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s illness, and amyotrophic lateral sclerosis (ALS). The corporate has an elaborate marketed product portfolio for MS, together with TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. It additionally markets SPINRAZA to deal with SMA, SKYCLARYS for the remedy of Friedreich’s Ataxia, and different medication.
Whereas we acknowledge the potential of BIIB as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back danger. When you’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.
